Marco Canevelli1, Giuseppe Bruno2, Giulia Grande3, Federica Quarata2, Riccardo Raganato2, Francesca Remiddi2, Martina Valletta2, Valerio Zaccaria2, Nicola Vanacore4, Matteo Cesari5. 1. Department of Human Neuroscience, "Sapienza" University, Rome, Italy; National Center for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy. Electronic address: marco.canevelli@gmail.com. 2. Department of Human Neuroscience, "Sapienza" University, Rome, Italy. 3. Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden. 4. National Center for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy. 5. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; Geriatric Unit, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy.
Abstract
INTRODUCTION: Race is an important health determinant and should adequately be considered in research and drug development protocols targeting Alzheimer's disease (AD). METHODS: A systematic review of available randomized controlled trials (RCTs) on the currently marketed treatments for AD was conducted with the aim of 1) documenting the reporting of race, and 2) exploring the impact of race on the efficacy and safety/tolerability of the considered medications. RESULTS: Overall, 59.2% of the 49 retained RCTs reported information concerning the race of participants. Only a striking minority of enrolled patients was constituted of blacks and Hispanics. None on the retained studies reported results on the efficacy and safety/tolerability of the tested treatment separately for racial groups nor performed sensitivity analyses accounting for the race of participants. DISCUSSION: Race has insufficiently been reported in previous interventional studies on AD. Its potential association with the effectiveness and safety/tolerability of the tested medications has completely been neglected.
INTRODUCTION: Race is an important health determinant and should adequately be considered in research and drug development protocols targeting Alzheimer's disease (AD). METHODS: A systematic review of available randomized controlled trials (RCTs) on the currently marketed treatments for AD was conducted with the aim of 1) documenting the reporting of race, and 2) exploring the impact of race on the efficacy and safety/tolerability of the considered medications. RESULTS: Overall, 59.2% of the 49 retained RCTs reported information concerning the race of participants. Only a striking minority of enrolled patients was constituted of blacks and Hispanics. None on the retained studies reported results on the efficacy and safety/tolerability of the tested treatment separately for racial groups nor performed sensitivity analyses accounting for the race of participants. DISCUSSION: Race has insufficiently been reported in previous interventional studies on AD. Its potential association with the effectiveness and safety/tolerability of the tested medications has completely been neglected.
Authors: Ana R Quiñones; Susan L Mitchell; Jonathan D Jackson; María P Aranda; Peggye Dilworth-Anderson; Ellen P McCarthy; Ladson Hinton Journal: J Am Geriatr Soc Date: 2020-07 Impact factor: 5.562
Authors: Elena Portacolone; Nynikka R Palmer; Peter Lichtenberg; Catherine M Waters; Carl V Hill; Sahru Keiser; Leah Vest; Marsha Maloof; Thi Tran; Paula Martinez; Javier Guerrero; Julene K Johnson Journal: Ethn Dis Date: 2020-11-19 Impact factor: 1.847
Authors: Miriam T Ashford; Rema Raman; Garrett Miller; Michael C Donohue; Ozioma C Okonkwo; Monica Rivera Mindt; Rachel L Nosheny; Godfrey A Coker; Ronald C Petersen; Paul S Aisen; Michael W Weiner Journal: Alzheimers Dement Date: 2022-02-25 Impact factor: 16.655
Authors: Miriam T Ashford; Joseph Eichenbaum; Tirzah Williams; Monica R Camacho; Juliet Fockler; Aaron Ulbricht; Derek Flenniken; Diana Truran; R Scott Mackin; Michael W Weiner; Rachel L Nosheny Journal: Alzheimers Dement (N Y) Date: 2020-05-26
Authors: María P Aranda; Ian N Kremer; Ladson Hinton; Julie Zissimopoulos; Rachel A Whitmer; Cynthia Huling Hummel; Laura Trejo; Chanee Fabius Journal: J Am Geriatr Soc Date: 2021-07 Impact factor: 7.538